Table 4.

Final population pharmacokinetics parameters for garenoxacin

Parameter	End of phase II stagea		End of phase III stageb		Bootstrap (n =1,000)c
	Model 2		Final model
CL/F (ml/min) CL/F = θ1 + θ2 × (CLCR − 102)			CL/F =  θ1 +  θ2 × (CLCR − 85) +  θ3 × (WT −  55)
θ1	66.7 ± 1.7		64.3 ± 1.25		65.3 (62.2 –76.3)
θ2	0.167 ± 0.036		0.213 ± 0.0309		0.184 (0.109 –0.261)
θ3	−		0.276 ± 0.113		0.328 (0.090–0.540)
V/F (l) V/F = θ4			V/F = θ4× (WT/55) θ5 +  θ6 × GEN
θ4	61.8 ± 1.7		53.9 ± 1.89		55.4 (49.8–68.4)
θ5	−		0.739 ± 0.104		0.502 (0.195 –0.873)
θ6	−		6.98 ± 1.88		8.02 (3.85–10.56)
ka (1/h)	4.72 ± 0.54		2.14 ± 0.223		2.16 (1.69–2.99)
	Coefficent of variance		Coefficient of variance
	Inter-individual variability		Inter-individual variability
ωCL/F 2	0.0424 ± 0.0097	20.6%	0.0403 ± 0.00748	20.1%	0.0374 (0.0149–0.0673)
ωV/F 2	0.0443 ± 0.0132	21.0%	0.0249 ± 0.00585	15.8%	0.156 (0.0181–0.3915)
ωCL/F,V/F	0.0330 ± 0.0115		0.0292 ± 0.00618		0.0096 (0.0036–0.0385)
	(r d = 0.761)		(r = 0.922)
ω2ka	2.63 ± 0.56	162%	0.411 ± 0.0863	64.1%	0.470 (0.269–1.073)
	Intra-individual variability			Intra-individual variability
σ2	0.0645 ± 0.0057	25.4%	0.105 ± 0.0060	32.4%	0.113 (0.095–0.162)

ka, First-order absorption rate constant

^aFirst-order method (NONMEM version V, level 1.0). Data are presented as the estimated value ± standard error

^bFirst-order conditional estimation method with interaction (NONMEM version VI, level 2.0). Data are presented as the estimated value ± standard error

^cData presented as median, with the 5−95% percentiles in parenthesis

^d r, Correlation coefficient